title: EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.
abstract: EBV-induced post transplantation lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after allogeneic hematopoietic cell transplantation. Profound T-cell depletion of the allograft represents a major risk factor for EBV-PTLD. With regard to the increasing use of alternative stem cell sources such as cord blood or purified haploidentical stem cell grafts both associated with impaired immune reconstitution, the frequent occurrence of EBV-PTLD demands particular vigilance on laboratory changes and early symptoms. Here we have summarized today's knowledge about EBV-PTLD in a comprehensive review explaining the underlying mechanisms of EBV-based transformation, EBV-PTLD development, clinical presentation, incidence, diagnosis, screening, therapy and prognosis. In this context, we emphasize on the necessity of regularly applied screening tools and pre-emptive treatment strategies including anti-CD20 Abs particularly in high-risk patients to avoid disease progression to malignant lymphoma. Although EBV-PTLD has always been associated with a high mortality rate, novel immunotherapeutic approaches such as the transfer of EBV-specific T cells nowadays offer improved chances of disease control even at late stages.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine II, Allogeneic Stem Cell Transplantation Center, Würzburg University Medical Center, Würzburg, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Rasche
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine II, Allogeneic Stem Cell Transplantation Center, Würzburg University Medical Center, Würzburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Kapp
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine II, Allogeneic Stem Cell Transplantation Center, Würzburg University Medical Center, Würzburg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Einsele
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine II, Allogeneic Stem Cell Transplantation Center, Würzburg University Medical Center, Würzburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Mielke
mesh_terms: D020031:Epstein-Barr Virus Infections / Q000150:complications*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000209:etiology; D012307:Risk Factors; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014182:Transplantation, Autologous / Q000009:adverse effects*